Here, we chose a different chemotherapy FGF401, which is a FGFR4 inhibitor by blocking the binding of ATP to the kinase domain of FGFR4 to prevent FGF19/FGFR4 aberrant activation that leads to eventually activation of Ras-Raf-ERK1/2 MAPK and PI3K-Akt pathways contributing to HCC progression 41. Here, FGF19 is linked to hepatocellular carcinoma.